The Role of Apolipoprotein E, Lipoprotein Receptors and CNS Lipid Homeostasis in Brain Aging and Alzheimers Disease (R01)

The summary for the The Role of Apolipoprotein E, Lipoprotein Receptors and CNS Lipid Homeostasis in Brain Aging and Alzheimers Disease (R01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

The Role of Apolipoprotein E, Lipoprotein Receptors and CNS Lipid Homeostasis in Brain Aging and Alzheimers Disease (R01): Purpose. This FOA encouarges multidisciplinary and interdisciplinary research to elucidate how Apolipoprotein E, lipoprotein receptors and CNS lipid homeostasis influence brain aging and the transition to neurodegeneration in Alzheimers disease (AD). The ultimate goal is to gain an in depth understanding of the mechanisms by which the Apolipoprotein E e4 allele confers increased AD risk for the purpose of advancing the overall search for efficacious AD treatments and Apolipoprotein E e4-directed therapeutics in particular. To this end we encourage research spanning multiple levels of analysis in multiple species (from mice to man).Studies aimed at identifying new therapeutic targets for the treatment of AD and other age-related neurodegenerative conditions associated with lipid neurobiology are strongly encouraged. Also of great interest are projects that aim to use lipidomics, various types of imaging and other cutting edge technologies to identify and develop early biomarkers of neurodegeneration associated lipid dyshomeostasis. Mechanism of Support. This FOA will utilize the R01 grant mechanism. Funds Available and Anticipated Number of Awards. During Fiscal Year 2010, the estimated amount of funds available to support projects under this FOA is $2,500,000.Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary.Given the likely range of budgets, it is anticipated that 4 to 7 awards could be made during Fiscal Year 2010.The availability of funds and the number of awards in future years will depend upon annual appropriations.

Federal Grant Title:	The Role of Apolipoprotein E, Lipoprotein Receptors and CNS Lipid Homeostasis in Brain Aging and Alzheimers Disease (R01)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PA-09-217
Type of Funding:	Grant
CFDA Numbers:	93.866
CFDA Descriptions:	Aging Research
Current Application Deadline:	Sep 07, 2012
Original Application Deadline:	Sep 07, 2012
Posted Date:	Jul 06, 2009
Creation Date:	Jul 06, 2009
Archive Date:	Oct 08, 2012
Total Program Funding:	$2,500,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants: • Nathan Shock Centers Coordinating Center (U24 Clinical Trial Not Allowed); • Nathan Shock Centers of Excellence in Basic Biology of Aging (P30 Clinical Trial Not Allow...; • Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (...; • Exploring Proteogenomic Approaches to Unravel the Mechanisms of Mis-Folded Protein Accumul...; • Research Training in Aging for Medical Students (T35); • Technological Enhancements and Archiving for Surveys of the Elderly: SBIR (R43/44) Initiat...; • Technological Enhancements and Archiving for Surveys of the Elderly: STTR (R41/42) Initiat...; • Technology and Aging: NIA Small Business Technology Transfer Program Initiative (STTR [R41...
More Grants from the National Institutes of Health: • Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Tri...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...; • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional)